Genome Diagnostics B.V., also known as GenDx, an Utrecht, the Netherlands-based provider of molecular diagnostic kits and analysis software for transplantation and companion diagnostics, received a minority, growth equity investment from Ampersand Capital Partners.
The amount of the deal was not disclosed. In connection with this transaction, David Parker, a General Partner at Ampersand, joined the GenDx Board of directors along with Ampersand Operating Partner Mike Evans, PhD.
The partnership between Ampersand and GenDx aims to foster sustainable growth, both organically and through M&A activities in the molecular diagnostic products and services market.
Led by Wietse Mulder, PhD., who remains the majority shareholder and CEO, Raoul Linschoten, LLM (Chairman), and Oscar Schoots, PhD., GenDx is a provider of molecular diagnostic kits and analysis software for transplantation and companion diagnostics.
The company specializes in HLA sequencing-based typing strategies and offers reagents and software for both Sanger and NGS approaches. In 2013, GenDx started developing and distributing products for chimerism monitoring by qPCR. Thanks to its extensive in-house expertise, the company also offers custom laboratory services for basic and clinical research organizations.
GenDx organizes dedicated HLA SBT and chimerism monitoring training courses worldwide on a regular basis for lab directors, lab managers, scientists and technicians working in tissue typing laboratories, blood banks, and donor registries.
Founded in 2005 by Erik Rozemuller PhD, Mulder and UMC Utrecht Holdings B.V. represented by Oscar Schoots PhD and Raoul Linschoten LLM, the company is based at the University Science Park in Utrecht, the Netherlands and also has an office near O’Hare airport, Chicago, IL (USA).
FinSMEs
09/05/2019